LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced that its Venezuelan subsidiary, LATAMEDAI VE, has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration aims to design, develop, test, and evaluate customized technology that supports workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis.
The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. The parties will begin by identifying specific workflows to be addressed, defining technical and operational requirements, and establishing a phased development and testing process. They also intend to establish confidentiality, information-security, data-management, and access-control procedures.
The technology is designed as a decision-support and workflow-management resource and will not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. Any pharmaceutical, scientific, laboratory, or quality-control determinations will remain the responsibility of appropriately qualified professionals and applicable regulatory authorities. Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized that the objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, and quality-control processes while preserving professional oversight.
Management believes this collaboration may provide an opportunity to expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications beyond its patient-facing telemedicine services. The initiative aligns with the Company's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, institutions, and other participants in the healthcare ecosystem. If successfully developed and implemented, the resulting technology may provide a framework adaptable for other organizations in Venezuela and Latin America, subject to separate agreements, successful development and testing, operational readiness, and regulatory requirements.
The parties will also evaluate ownership, licensing, permitted use, and protection of any intellectual property developed through the collaboration. The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation schedule, commercial deployment, reduction in operating costs or development timelines, scientific or regulatory outcomes, revenue, profitability, or expansion. LataMed AI will provide additional information regarding development, testing, and potential implementation as appropriate. For more information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
